Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Xilio Therapeutics (NASDAQ:XLO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Institutional & Insider Ownership
4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 0.9% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 7.4% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Valion Bio, Inc. Common Stock and Xilio Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
| Xilio Therapeutics | -34.06% | -71.99% | -20.43% |
Valuation and Earnings
This table compares Valion Bio, Inc. Common Stock and Xilio Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 0.60 | -$8.88 million | ($159.25) | -0.00 |
| Xilio Therapeutics | $43.77 million | 1.28 | -$35.04 million | ($1.64) | -5.20 |
Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Valion Bio, Inc. Common Stock and Xilio Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| Xilio Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Xilio Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 87.57%. Given Xilio Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Valion Bio, Inc. Common Stock.
Risk and Volatility
Valion Bio, Inc. Common Stock has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.
Summary
Xilio Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 13 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About Xilio Therapeutics
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects. Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
